Literature DB >> 9420201

The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge.

T Peng1, M Ponce-de-Leon, H Jiang, G Dubin, J M Lubinski, R J Eisenberg, G H Cohen.   

Abstract

The herpes simplex virus type 1 (HSV-1) gH-gL complex which is found in the virion envelope is essential for virus infectivity and is a major antigen for the host immune system. However, little is known about the precise role of gH-gL in virus entry, and attempts to demonstrate the immunologic or vaccine efficacy of gH and gL separately or as the gH-gL complex have not succeeded. We constructed a recombinant mammalian cell line (HL-7) which secretes a soluble gH-gL complex, consisting of gH truncated at amino acid 792 (gHt) and full-length gL. Purified gHt-gL reacted with gH- and gL-specific monoclonal antibodies, including LP11, which indicates that it retains its proper antigenic structure. Soluble forms of gD (gDt) block HSV infection by interacting with specific cellular receptors. Unlike soluble gD, gHt-gL did not block HSV-1 entry into cells, nor did it enhance the blocking capacity of gD. However, polyclonal antibodies to the complex did block entry even when added after virus attachment. In addition, these antibodies exhibited high titers of complement-independent neutralizing activity against HSV-1. These sera also cross-neutralized HSV-2, albeit at low titers, and cross-reacted with gH-2 present in extracts of HSV-2-infected cells. To test the potential for gHt-gL to function as a vaccine, BALB/c mice were immunized with the complex. As controls, other mice were immunized with gD purified from HSV-infected cells or were sham immunized. Sera from the gD- or gHt-gL-immunized mice exhibited high titers of virus neutralizing activity. Using a zosteriform model of infection, we challenged mice with HSV-1. All animals showed some evidence of infection at the site of virus challenge. Mice immunized with either gD or gHt-gL showed reduced primary lesions and exhibited no secondary zosteriform lesions. The sham-immunized control animals exhibited extensive secondary lesions. Furthermore, mice immunized with either gD or gHt-gL survived virus challenge, while many control animals died. These results suggest that gHt-gL is biologically active and may be a candidate for use as a subunit vaccine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9420201      PMCID: PMC109350     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  57 in total

1.  Glycoprotein H of pseudorabies virus is essential for entry and cell-to-cell spread of the virus.

Authors:  B Peeters; N de Wind; R Broer; A Gielkens; R Moormann
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

2.  High-level expression and purification of secreted forms of herpes simplex virus type 1 glycoprotein gD synthesized by baculovirus-infected insect cells.

Authors:  W P Sisk; J D Bradley; R J Leipold; A M Stoltzfus; M Ponce de Leon; M Hilf; C Peng; G H Cohen; R J Eisenberg
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

3.  Coexpression of truncated human cytomegalovirus gH with the UL115 gene product or the truncated human fibroblast growth factor receptor results in transport of gH to the cell surface.

Authors:  R R Spaete; K Perot; P I Scott; J A Nelson; M F Stinski; C Pachl
Journal:  Virology       Date:  1993-04       Impact factor: 3.616

4.  Herpes simplex virus type 1 entry through a cascade of virus-cell interactions requires different roles of gD and gH in penetration.

Authors:  A O Fuller; W C Lee
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

5.  Glycoprotein H of human cytomegalovirus (HCMV) forms a stable complex with the HCMV UL115 gene product.

Authors:  J F Kaye; U A Gompels; A C Minson
Journal:  J Gen Virol       Date:  1992-10       Impact factor: 3.891

6.  A mutant herpes simplex virus type 1 unable to express glycoprotein L cannot enter cells, and its particles lack glycoprotein H.

Authors:  C Roop; L Hutchinson; D C Johnson
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

7.  Construction and properties of a mutant of herpes simplex virus type 1 with glycoprotein H coding sequences deleted.

Authors:  A Forrester; H Farrell; G Wilkinson; J Kaye; N Davis-Poynter; T Minson
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

8.  Neutralization epitope of the varicella-zoster virus gH:gL glycoprotein complex.

Authors:  B Forghani; L Ni; C Grose
Journal:  Virology       Date:  1994-03       Impact factor: 3.616

9.  A novel herpes simplex virus glycoprotein, gL, forms a complex with glycoprotein H (gH) and affects normal folding and surface expression of gH.

Authors:  L Hutchinson; H Browne; V Wargent; N Davis-Poynter; S Primorac; K Goldsmith; A C Minson; D C Johnson
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

10.  Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gE, gG, gH, and gI): comparative protection against lethal challenge in mice.

Authors:  H Ghiasi; R Kaiwar; A B Nesburn; S Slanina; S L Wechsler
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

View more
  51 in total

Review 1.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part I. HSV-1 structure, replication and pathogenesis.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

2.  The genes encoding the gCIII complex of human cytomegalovirus exist in highly diverse combinations in clinical isolates.

Authors:  Lucy Rasmussen; Aimee Geissler; Catherine Cowan; Amanda Chase; Mark Winters
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

3.  Structure-based analysis of the herpes simplex virus glycoprotein D binding site present on herpesvirus entry mediator HveA (HVEM).

Authors:  Sarah A Connolly; Daniel J Landsburg; Andrea Carfi; Don C Wiley; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

4.  Specific association of glycoprotein B with lipid rafts during herpes simplex virus entry.

Authors:  Florent C Bender; J Charles Whitbeck; Manuel Ponce de Leon; Huan Lou; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

5.  Cellular and viral requirements for rapid endocytic entry of herpes simplex virus.

Authors:  Anthony V Nicola; Stephen E Straus
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

6.  Cascade of events governing cell-cell fusion induced by herpes simplex virus glycoproteins gD, gH/gL, and gB.

Authors:  Doina Atanasiu; Wan Ting Saw; Gary H Cohen; Roselyn J Eisenberg
Journal:  J Virol       Date:  2010-09-22       Impact factor: 5.103

7.  Bimolecular complementation reveals that glycoproteins gB and gH/gL of herpes simplex virus interact with each other during cell fusion.

Authors:  Doina Atanasiu; J Charles Whitbeck; Tina M Cairns; Brigid Reilly; Gary H Cohen; Roselyn J Eisenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-14       Impact factor: 11.205

8.  Herpes simplex virus glycoprotein B associates with target membranes via its fusion loops.

Authors:  Brian P Hannah; Tina M Cairns; Florent C Bender; J Charles Whitbeck; Huan Lou; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2009-04-15       Impact factor: 5.103

9.  Insertion mutations in herpes simplex virus 1 glycoprotein H reduce cell surface expression, slow the rate of cell fusion, or abrogate functions in cell fusion and viral entry.

Authors:  Julia O Jackson; Erick Lin; Patricia G Spear; Richard Longnecker
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

10.  Structural and antigenic analysis of a truncated form of the herpes simplex virus glycoprotein gH-gL complex.

Authors:  T Peng; M Ponce de Leon; M J Novotny; H Jiang; J D Lambris; G Dubin; P G Spear; G H Cohen; R J Eisenberg
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.